CSL Profit Margin 2017-2021 | CSLLY
Current and historical gross margin, operating margin and net profit margin for CSL (CSLLY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. CSL net profit margin as of June 30, 2021 is 0%.
|CSL Annual Profit Margins
|CSL Quarterly Profit Margins
||Medical - Biomedical and Genetics
CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company's operating segments consists of CSL Behring and bioCSL. CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. bioCSL segment manufactures, sells and distributes vaccines, antivenoms and other pharmaceutical products primarily in Australia and New Zealand; as well as also manufactures and markets in vitro diagnostic products through Immunohaematology. It operates primarily in Germany, Switzerland and the United States. CSL Ltd. is headquartered in Parkville, Australia.